查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2003059

PARP抑制剂药物治疗市场：按药物、适应症、治疗阶段、治疗环境、治疗方法、患者年龄层、最终用户和分销管道划分——2026年至2032年全球市场预测

PARP Inhibitors Drug Therapy Market by Drug, Indication, Line Of Therapy, Treatment Setting, Therapy Type, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年 PARP 抑制剂药物治疗市场价值为 78 亿美元，预计到 2026 年将成长至 83.3 亿美元，复合年增长率为 9.88%，到 2032 年将达到 151.1 亿美元。

主要市场统计数据
基准年 2025 78亿美元
预计年份：2026年 83.3亿美元
预测年份：2032年 151.1亿美元
复合年增长率 (%) 9.88%

PARP抑制剂疗法的全面应用：重点关注影响肿瘤医学领域应用的临床证据、监管里程碑和应用趋势。

随着标靶癌症治疗的发展，PARP抑制剂已成为精准医疗的前沿药物，其适应症不断扩大，临床应用也日益成熟。本文概述了PARP抑制的治疗原理、目前这些药物影响最大的临床领域，以及推动其应用推广的众多相关人员。本文并非着眼于量化市场规模，而是聚焦于药物的作用机制、监管里程碑和临床终点，旨在帮助读者更好地理解PARP抑制剂的治疗背景。

对重塑 PARP 抑制剂的临床实践、开发策略、监管管道和获取模式的关键变革性变化进行详细分析。

在生物标记科学的进步、联合治疗的开发以及法规结构的不断完善的推动下，PARP抑制剂疗法的前景正在发生变革性变化。特别是，BRCA突变生物标记的改进以及更广泛的同源重组缺陷特征的出现，不仅扩大了PARP抑制剂的临床应用范围，也提高了患者选择的精确度。随着基因组分析被纳入临床决策的早期阶段，临床医生能够更好地识别PARP标靶治疗的候选患者，并合理安排以标靶治疗和免疫肿瘤药物为中心的治疗方案。

检验到 2025 年美国累积实施的关税对药品供应链、商业策略、准入考量和支付方参与的影响。

美国实施的累积关税政策将持续到2025年，为医药供应链带来了许多成本压力，影响了采购、定价策略以及与相关人员的谈判。这些关税措施影响了活性成分的采购、成品的进口以及相关医疗用品，促使许多製造商和经销商重新评估供应商多元化、库存管理以及与全球合作伙伴的合约条款。製造地集中在美国境外的公司面临独特的压力，需要调整其物流系统，以减轻支付方和医疗服务提供者的成本负担。

将适应症、生物标记概况、药物特性、治疗线、治疗环境和分销管道与临床和商业策略联繫起来的详细细分见解。

为了解PARP抑制剂作用于不同患者群体和临床背景，从适应症层面进行精准的分类至关重要。在乳癌中，依受体类型进行分层可区分荷尔蒙受体阳性和三阴性乳癌，二者有不同的反应模式，并对治疗顺序产生不同的影响。在卵巢癌中，必须密切注意生物标记状态，因为BRCA突变阳性、同源重组缺陷（HRD）阳性和非HRD患者群体对PARP标靶治疗方法的敏感性各不相同。在胰臟癌中，基于分期的分类可区分晚期和早期患者，从而影响维持治疗的可行性和临床试验的合格。同样，基于分期的分类在前列腺癌中也至关重要，区分转移性和非转移性疾病会改变终点指标、生存预测以及与雄激素受体标靶治疗治疗联合用药的策略。

关键区域洞察突显了美洲、欧洲、中东和非洲以及亚太地区在监管、诊断和支付方优先事项方面的差异如何影响 PARP 抑制剂的采用。

区域趋势影响PARP抑制剂的研发、核准和上市，每个地区都存在独特的临床实践、监管预期和支付方环境。在美洲，监管机构和支付方优先考虑疗效比较和真实世界临床表现，而临床应用则受到成熟的基因组检测管道和高度普及的综合专科药房服务的影响。这些因素共同创造了一种环境，在这种环境下，差异化的临床证据和以支付方为中心的价值论证对治疗可及性的影响尤其显着。

本文揭示了临床开发合作、诊断伙伴关係和商业模式如何使每家公司在 PARP 抑制剂专案上采取不同的策略。

对PARP抑制剂领域主要企业的深入检验揭示了它们在研发重点、临床证据生成和商业性定位方面的策略多样性。一些企业专注于透过基于生物标记的适应症拓展和联合治疗研究来扩大适应症范围，而另一些企业则优先考虑安全性差异化和患者支持，以维持口服药物的依从性。为了寻求互补的专业知识，例如将伙伴关係抑制剂与免疫肿瘤疗法或血管生成抑制剂结合，以实现协同效应并分散临床风险，策略联盟和联合开发伙伴关係十分常见。

为产业领导者提供实用建议，以整合生物标记策略，增强真实世界证据供应链的韧性，并提高支付方在 PARP 抑制剂计画中的参与度。

产业领导者应优先采取以下几项切实可行的措施，以提升PARP抑制剂的临床、商业和营运绩效。首先，至关重要的是将全面的生物标记策略贯穿从早期研发到商业化的整个过程。这包括支持诊断规模化、确保及时报销检测费用，以及投资临床医生教育，以缩短从诊断到治疗的延误时间。透过这些措施，企业可以提高合适患者的识别率，并提升治疗启动的效率。

这种严谨的调查方法详细介绍如何整合一级和二级证据、专家访谈以及品质保证措施，以分析 PARP 抑制剂的临床和商业性趋势。

本分析的调查方法结合了多来源证据和定性专家见解，从而对PARP抑制剂疗法提供了全面的观点。主要调查包括对肿瘤科医生、医院药剂师、专科药房经理和保险公司顾问进行结构化访谈，以了解他们对诊断流程、治疗顺序和用药障碍的实际观点。此外，还对同行评审的临床文献、监管文件和指南进行了系统性回顾，以确保其与目前的临床标准和安全性数据保持一致。

一项权威的综合分析重点阐述了基于生物标记科学的证据生成和综合商业化策略将如何决定 PARP 抑制剂未来的普及和影响。

总之，PARP抑制剂是一类成熟但仍在不断发展的分子标靶癌症疗法，在生物标记定义的患者群体中展现出显着的临床疗效。未来，基因组诊断的进步、联合治疗策略的测试以及为解决支付方和医疗服务提供方的担忧而收集的可靠真实世界数据，将共同塑造此类药物的未来发展。相关人员必须了解区域监管和报销政策，适应不断变化的经销和治疗环境，并预见宏观经济和贸易政策变化可能带来的供应链压力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：PARP抑制剂药物治疗市场：依药物分类

  • 细香葱
  • 奥拉帕尼
  • 卢卡帕利
  • 塔拉索帕利

第九章：PARP抑制剂药物治疗市场：依适应症划分

  • 乳癌
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌

第十章：PARP抑制剂药物治疗市场：依治疗阶段划分

  • 一线治疗
  • 维持治疗
  • 后续治疗阶段

第十一章 PARP抑制剂药物治疗市场：依治疗环境划分

  • 住院治疗
  • 门诊

第十二章 PARP抑制剂药物治疗市场：依治疗方法划分

  • 联合治疗
  • 单药治疗

第十三章：PARP抑制剂药物治疗市场：依患者年龄组别划分

  • 成人
  • 老年人

第十四章 PARP抑制剂药物治疗市场：依最终用户划分

  • 医院
  • 零售药房
  • 专科诊所

第十五章：PARP抑制剂药物治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十六章：PARP抑制剂药物治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 PARP抑制剂药物治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章：PARP抑制剂药物治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国PARP抑制剂药物治疗市场

第二十章：中国PARP抑制剂药物治疗市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Artios Pharma Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Checkpoint Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Guardian Therapeutics Inc.
  • IMPACT Therapeutics
  • JEIL PHARMACEUTICAL CO., LTD.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Olympus Corporation
  • ONO PHARMACEUTICAL CO., LTD.
  • Pfizer Inc.
  • Repare Therapeutics Inc.
  • Ribon Therapeutics, Inc.
  • Sanofi SA
  • SyntheX Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zai Lab Limited
Product Code: MRR-AD517FAA716F

The PARP Inhibitors Drug Therapy Market was valued at USD 7.80 billion in 2025 and is projected to grow to USD 8.33 billion in 2026, with a CAGR of 9.88%, reaching USD 15.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.80 billion
Estimated Year [2026] USD 8.33 billion
Forecast Year [2032] USD 15.11 billion
CAGR (%) 9.88%

Comprehensive introduction to PARP inhibitor therapeutics emphasizing clinical rationale regulatory milestones and delivery dynamics shaping adoption across oncology care

The evolution of targeted oncology therapeutics has placed PARP inhibitors at the forefront of precision medicine, with expanding indications and increasing clinical sophistication. This introduction outlines the therapeutic rationale behind PARP inhibition, the current clinical corridors where these agents exert the most impact, and the broader ecosystem of stakeholders shaping their adoption. It situates readers within the therapeutic context without attempting to quantify market size, instead emphasizing mechanisms of action, regulatory landmarks, and clinical endpoints that drive decision-making.

PARP inhibitors exploit tumor-specific vulnerabilities in DNA damage repair pathways, creating synthetic lethality in cancers reliant on homologous recombination deficiencies. Their clinical utility spans several solid tumors with distinct biomarker profiles and disease stages. From initial monotherapy approvals to contemporary combination regimens and maintenance strategies, the PARP class has demonstrated durable responses in selected patient subsets and become a viable option across multiple lines of therapy. This introduction highlights those clinical inflection points and prepares the reader to understand how indication, biomarker status, and therapeutic context influence development and commercialization.

Concurrently, healthcare delivery trends-ranging from outpatient oncology infusion expansion to shifts in specialty pharmacy distribution-are reshaping how PARP inhibitors reach patients. Payer expectations and real-world evidence initiatives increasingly inform treatment algorithms, while clinician practice patterns adapt to evolving guideline recommendations. This section sets the stage for a deeper exploration of transformative shifts, segmentation nuances, regulatory and reimbursement dynamics, and practical recommendations for stakeholders seeking to navigate the complexity of PARP inhibitor deployment across therapeutic settings.

Detailed analysis of the major transformative shifts reshaping PARP inhibitor clinical practice development strategies regulatory pathways and access models

The landscape of PARP inhibitor therapy is undergoing transformative shifts driven by advances in biomarker science, combination therapy development, and evolving regulatory frameworks. Biomarker refinement, particularly around BRCA mutations and broader homologous recombination deficiency signatures, has expanded both the clinical rationale for use and the precision of patient selection. As genomic profiling becomes integrated into earlier lines of clinical decision-making, clinicians are better able to identify candidates for PARP-directed interventions and to sequence therapies around targeted and immuno-oncology agents.

Simultaneously, the therapeutic paradigm is moving from single-agent maintenance strategies to more complex combination regimens that pair PARP inhibitors with anti-angiogenics, immune checkpoint inhibitors, or cytotoxic agents. These combinations aim to broaden the responsive patient population and enhance depth of response, but they also introduce new considerations in safety management, dosing optimization, and payer negotiation. Regulatory pathways have adapted to these developments with label expansions tied to biomarker-defined populations and accelerated approvals that require robust confirmatory evidence; this regulatory dynamism influences clinical trial design and commercial planning alike.

Delivery models are shifting as well. The rise of outpatient and specialty clinic administration, coupled with expanded roles for retail and online pharmacy distribution channels, affects patient access and adherence. Real-world evidence programs and post-approval studies are increasing in importance as stakeholders seek to validate long-term outcomes, comparative effectiveness, and value propositions. Taken together, these shifts are redefining clinical pathways and commercial strategies, requiring agile cross-functional teams to align clinical development, regulatory engagement, and payer communication in order to maximize therapeutic impact.

Examination of how cumulative United States tariffs implemented through 2025 influenced pharmaceutical supply chains commercial strategies access considerations and payer engagement

The imposition of cumulative tariffs in the United States through 2025 introduced a range of cost headwinds for pharmaceutical supply chains, with implications for procurement, pricing strategies, and stakeholder negotiations. These tariff measures affected active pharmaceutical ingredient sourcing, finished product imports, and ancillary medical supplies, prompting many manufacturers and distributors to reassess supplier diversification, inventory management, and contractual terms with global partners. Companies with concentrated manufacturing footprints outside the U.S. faced discrete pressures to adapt logistics and mitigate cost pass-through to payers and providers.

In response, many stakeholders prioritized supply chain resiliency by identifying alternate manufacturing sites, nearshoring critical components, and renegotiating vendor contracts to secure longer-term price certainty. Payers and integrated delivery networks increased scrutiny on unit costs and therapy affordability, accelerating adoption of value-based contracting approaches and outcomes-based reimbursement pilots. At the provider level, institutions revisited formulary placement and chemotherapy pathway protocols to preserve therapeutic continuity while managing budgetary constraints.

Clinically, the tariff-driven environment reinforced the importance of demonstrating differential value across PARP agents, particularly where therapeutic interchangeability is debated. Real-world evidence collection and pharmacoeconomic modeling became more central to payer discussions, shaping coverage and prior authorization workflows. These collective adjustments underscore how macroeconomic and trade policies can exert downstream pressure on innovation adoption, necessitating proactive supply chain strategies, rigorous value demonstration, and collaborative engagement with payers and providers to sustain patient access during periods of external cost volatility.

In-depth segmentation insights that connect indication biomarker profiles drug characteristics lines of therapy treatment settings and distribution channels to clinical and commercial strategies

Robust segmentation is essential to understand the heterogeneous patient populations and clinical contexts in which PARP inhibitors operate, beginning with indication-level distinctions. In breast cancer, stratification by receptor type separates hormone receptor-positive disease from triple-negative disease, each with distinct responsiveness patterns and therapeutic sequencing implications. Ovarian cancer requires granular attention to biomarker status, with BRCA-mutated, homologous recombination deficiency-positive, and non-HRD cohorts showing varied sensitivity to PARP-directed approaches. Pancreatic cancer segmentation by stage distinguishes patients with advanced disease from those in earlier stages, which influences the feasibility of maintenance strategies and trial eligibility. Prostate cancer similarly pivots on stage differentiation, separating metastatic from non-metastatic disease and altering endpoints, survival expectations, and integration with androgen receptor-targeted therapies.

Drug-level differentiation among Niraparib, Olaparib, Rucaparib, and Talazoparib drives clinical positioning based on pharmacologic profiles, dosing schedules, safety signals, and approved or investigational indications. Line-of-therapy segmentation-first line, maintenance, and subsequent lines-affects objectives of treatment, whether induction of response, prolongation of progression-free intervals, or salvage therapy after resistance. Treatment setting is another critical axis: inpatient versus outpatient contexts shape administration logistics, monitoring resources, and the role of infusion centers versus oral therapy management in ambulatory oncology practices.

End users such as hospitals, retail pharmacies, and specialty clinics interact with distribution channels including hospital pharmacies, online pharmacies, and retail pharmacy networks, creating diverse access pathways and adherence touchpoints. Therapy type divides into combination therapy and monotherapy considerations, which impact safety management and payer negotiations. Finally, patient age group segmentation into adults and elderly introduces differences in comorbidity burden, polypharmacy risks, and real-world tolerability that must inform clinical protocols and patient support programs. Integrating these layered segmentation lenses supports more precise clinical trial cohorts, sharper value narratives for payers, and tailored patient support models that enhance adherence and outcomes.

Key regional insights highlighting how Americas Europe Middle East Africa and Asia-Pacific differences in regulation diagnostics and payer priorities shape PARP inhibitor adoption

Regional dynamics shape how PARP inhibitors are developed, approved, and adopted, with each geography presenting distinct clinical practices, regulatory expectations, and payer landscapes. In the Americas, regulatory authorities and payers emphasize comparative effectiveness and real-world performance, while clinical adoption is influenced by established genomic testing pathways and a high prevalence of integrated specialty pharmacy services. These factors create an environment where differentiated clinical evidence and payer-centric value demonstration are particularly influential in shaping treatment access.

Across Europe, the Middle East, and Africa, heterogeneity in regulatory frameworks and reimbursement systems requires localized evidence generation and nuanced health technology assessment engagement. Variability in genomic testing infrastructure and resource allocation means that uptake can differ substantially even within contiguous markets, driving the need for tailored access strategies, local investigator partnerships, and adaptive pricing approaches that reflect country-level health priorities. In contrast, the Asia-Pacific region presents a mix of rapidly modernizing markets with growing genomic diagnostics capacity and jurisdictions where infrastructure constraints limit the speed of adoption. This diversity necessitates a multifaceted regional strategy that balances centralized clinical development with country-specific access planning and engagement with regional key opinion leaders to support guideline inclusion and testing scale-up.

Across all regions, collaborations between industry, clinical societies, and payers to expand testing access and to integrate PARP inhibitors into standardized treatment pathways influence uptake. Cross-border clinical trial networks and data-sharing initiatives also contribute to the evidence base, enabling broader understanding of safety profiles and long-term outcomes. Recognizing and addressing regional differences in regulatory timing, diagnostic availability, and payer priorities is crucial for effective global program planning and for ensuring equitable patient access to PARP-directed therapies.

Key corporate strategic insights revealing how clinical development alliances diagnostic partnerships and commercial models differentiate company approaches to PARP inhibitor programs

A focused review of key companies active in the PARP inhibitor space reveals strategic diversity in development priorities, clinical evidence generation, and commercial positioning. Some organizations have concentrated on broadening label indications by pursuing biomarker-driven expansions and combination studies, while others emphasize safety differentiation and patient support infrastructures to maintain adherence in oral regimens. Strategic alliances and co-development partnerships have been common as firms seek complementary expertise-such as combining PARP inhibitors with immuno-oncology programs or angiogenesis inhibitors-to pursue synergistic effects and to diversify clinical risk.

Manufacturers are also investing in diagnostics partnerships to ensure upstream identification of eligible populations, recognizing that timely genomic testing is foundational to uptake. Companies with vertically integrated approaches, linking diagnostic capabilities with therapeutic offerings, are better positioned to reduce friction in the patient pathway. Competitive dynamics hinge on demonstrating robustness of data across different indications and on articulating clear value propositions that resonate with payers and providers; head-to-head evidence remains limited, so indirect comparisons and real-world analyses are increasingly used to support positioning.

Commercial strategies vary from centralized specialty pharmacy models that emphasize adherence support to broader retail distribution supported by digital patient engagement tools. Across the industry, there is a growing focus on sequencing strategies that consider prior treatments, potential cross-resistance, and tolerability profiles in older populations. These strategic variations underscore that successful execution requires alignment across clinical development, diagnostics, commercial operations, and payer engagement to translate clinical promise into sustainable patient access.

Actionable recommendations for industry leaders to integrate biomarker strategies enhance real-world evidence supply chain resilience and payer engagement for PARP inhibitor programs

Industry leaders should prioritize several actionable steps to strengthen clinical, commercial, and operational performance around PARP inhibitors. First, integrating comprehensive biomarker strategies from early development through commercialization is essential; this includes supporting diagnostic scale-up, ensuring timely test reimbursement, and investing in clinician education to reduce diagnostic-to-treatment delays. By doing so, organizations can increase identification of appropriate patients and improve the efficiency of therapeutic deployment.

Second, sponsors should pursue robust real-world evidence programs that complement clinical trials, focusing on comparative effectiveness, long-term safety, and health-related quality of life. These data will be instrumental in payer negotiations and in informing best-practice guidelines. Third, building flexible supply chains that accommodate potential trade and tariff-related disruptions enhances resilience; diversification of manufacturing sites and strategic inventory management reduce the risk of therapy shortages and price volatility.

Fourth, commercial teams must craft differentiated value narratives that address payer concerns without relying solely on list-price arguments, emphasizing measurable outcomes, reduction in downstream resource utilization, and patient-reported benefits. Fifth, consider modular patient support programs that address adherence, toxicity management, and logistics for elderly populations with comorbidities. Finally, engage early and transparently with health authorities and payers to align evidence generation with reimbursement requirements, and to design outcomes-based agreements where appropriate. Collectively, these actions foster more predictable access pathways and stronger alignment between clinical benefits and economic value.

Rigorous research methodology detailing primary and secondary evidence synthesis expert interviews and quality assurance measures used to analyze PARP inhibitor clinical and commercial dynamics

The research methodology underpinning this analysis combined a multi-source evidence synthesis with qualitative expert input to produce a comprehensive perspective on PARP inhibitor therapeutics. Primary research included structured interviews with oncology clinicians, hospital pharmacists, specialty pharmacy managers, and payer advisors to capture frontline perspectives on diagnostic workflows, treatment sequencing, and access barriers. These insights were complemented by systematic reviews of peer-reviewed clinical literature, regulatory documents, and guideline statements to ensure alignment with current clinical standards and safety data.

Secondary analysis incorporated publicly available clinical trial registries, regulatory announcements, and real-world evidence publications to track label changes, key trial outcomes, and post-approval studies. Attention was paid to heterogeneity in study populations and biomarker definitions to ensure accurate interpretation. Analytical frameworks assessed therapy positioning across lines of care, safety and tolerability trade-offs, and commercial access considerations, while scenario planning explored implications of supply chain disruptions and evolving payer expectations.

Quality assurance processes included cross-validation of interview findings against published data, triangulation of regulatory sources, and internal expert review to surface any inconsistencies or gaps. The methodology emphasized transparency about data sources and limitations, particularly where head-to-head comparative evidence remains limited, and prioritized evidence that directly informs clinical decision-making, payer dialogues, and operational planning for stakeholders involved in PARP inhibitor development and commercialization.

Conclusive synthesis highlighting how biomarker science evidence generation and integrated commercialization strategies will determine the future adoption and impact of PARP inhibitors

In conclusion, PARP inhibitors represent a mature yet evolving class of targeted oncology therapies with meaningful clinical impact in biomarker-defined populations. The trajectory of the class is shaped by advances in genomic diagnostics, strategic combination trials, and the need for compelling real-world evidence to address payer and provider questions. Stakeholders must navigate region-specific regulatory and reimbursement landscapes, adapt to shifts in distribution and treatment settings, and anticipate supply chain pressures that may arise from macroeconomic and trade policy changes.

Success in this environment depends on integrated strategies that connect diagnostics, clinical development, and commercial execution. Prioritizing patient identification through reliable testing pathways, investing in evidence that demonstrates value beyond surrogate endpoints, and designing patient-centric support programs will collectively enhance adoption and long-term treatment continuity. Collaborative approaches involving industry, clinical societies, payers, and healthcare providers can accelerate guideline incorporation and broaden appropriate access while maintaining fiscal sustainability.

Ultimately, the continued evolution of PARP inhibitor therapy will be determined by the strength of biomarker science, the ability to demonstrate meaningful clinical and real-world outcomes, and the agility of organizations to align manufacturing, distribution, and payer engagement with rapidly changing clinical needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PARP Inhibitors Drug Therapy Market, by Drug

  • 8.1. Niraparib
  • 8.2. Olaparib
  • 8.3. Rucaparib
  • 8.4. Talazoparib

9. PARP Inhibitors Drug Therapy Market, by Indication

  • 9.1. Breast Cancer
  • 9.2. Ovarian Cancer
  • 9.3. Pancreatic Cancer
  • 9.4. Prostate Cancer

10. PARP Inhibitors Drug Therapy Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Maintenance
  • 10.3. Subsequent Line

11. PARP Inhibitors Drug Therapy Market, by Treatment Setting

  • 11.1. Inpatient
  • 11.2. Outpatient

12. PARP Inhibitors Drug Therapy Market, by Therapy Type

  • 12.1. Combination Therapy
  • 12.2. Monotherapy

13. PARP Inhibitors Drug Therapy Market, by Patient Age Group

  • 13.1. Adults
  • 13.2. Elderly

14. PARP Inhibitors Drug Therapy Market, by End User

  • 14.1. Hospitals
  • 14.2. Retail Pharmacies
  • 14.3. Specialty Clinics

15. PARP Inhibitors Drug Therapy Market, by Distribution Channel

  • 15.1. Hospital Pharmacies
  • 15.2. Online Pharmacies
  • 15.3. Retail Pharmacies

16. PARP Inhibitors Drug Therapy Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. PARP Inhibitors Drug Therapy Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. PARP Inhibitors Drug Therapy Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States PARP Inhibitors Drug Therapy Market

20. China PARP Inhibitors Drug Therapy Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AbbVie Inc.
  • 21.6. Amgen Inc.
  • 21.7. Artios Pharma Ltd.
  • 21.8. Astellas Pharma Inc.
  • 21.9. AstraZeneca plc
  • 21.10. Bayer AG
  • 21.11. BeiGene, Ltd.
  • 21.12. Biogen Inc.
  • 21.13. Bristol-Myers Squibb Company
  • 21.14. Checkpoint Therapeutics, Inc.
  • 21.15. Clovis Oncology, Inc.
  • 21.16. Daiichi Sankyo Company, Limited
  • 21.17. Eisai Co., Ltd.
  • 21.18. Eli Lilly and Company
  • 21.19. F. Hoffmann-La Roche Ltd.
  • 21.20. Genentech, Inc.
  • 21.21. GlaxoSmithKline plc
  • 21.22. Guardian Therapeutics Inc.
  • 21.23. IMPACT Therapeutics
  • 21.24. JEIL PHARMACEUTICAL CO., LTD.
  • 21.25. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 21.26. Johnson & Johnson Services, Inc.
  • 21.27. Karyopharm Therapeutics Inc.
  • 21.28. Kyowa Kirin Co., Ltd.
  • 21.29. Merck & Co., Inc.
  • 21.30. Merck KGaA
  • 21.31. Myriad Genetics, Inc.
  • 21.32. Novartis AG
  • 21.33. Olympus Corporation
  • 21.34. ONO PHARMACEUTICAL CO., LTD.
  • 21.35. Pfizer Inc.
  • 21.36. Repare Therapeutics Inc.
  • 21.37. Ribon Therapeutics, Inc.
  • 21.38. Sanofi S.A.
  • 21.39. SyntheX Inc.
  • 21.40. Takeda Pharmaceutical Company Limited
  • 21.41. Teva Pharmaceutical Industries Ltd.
  • 21.42. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 164. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 167. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 191. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 194. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 200. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 203. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)